echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hualan biological four-price influenza vaccine in 2019 rapid release of blood products solid growth.

    Hualan biological four-price influenza vaccine in 2019 rapid release of blood products solid growth.

    • Last Update: 2020-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On March 23, Hualan Bio released its 2019 annual report, with full-year operating income of RMB3.7 billion, up 15.02% YoY; net profit attributable to shareholders of listed companies was RMB1.283 billion, up 12.63% YoY;
    announcement shows that Hualan biological vaccine products gross margin reached more than 85%, revenue increased by 30.77 percent over the same period last year, mainly due to the rapid release of the tetravalent influenza virus lysis vaccine, the first line officially began production, a total of 835.93 million four-price influenza vaccines were issued during the reporting period, a total of nearly 13 million influenza vaccines were issued, accounting for 42% of the national influenza vaccine issued.
    at present, Hualan biology is also involved in the development of a new coronavirus vaccine.
    blood products continued to grow solidly, with a gross margin of 57.14 per cent and revenue of 9.77 per cent year-on-year.
    core products human hemoglobin and glycium acetone growth of more than 10%, 60%.
    revenue from fine cinge ball has increased significantly, and destocking has been basically completed.
    the outbreak of new crown pneumonia is still continuing, blood products become the recommended varieties of anti-epidemic drugs.
    in the first quarter of this year, a significant increase in demand for glycolobin and human hemoglobin may present some opportunities for blood products companies.
    at the same time the outbreak also brought difficulties to blood products, domestic and foreign pulp production is affected by the outbreak decline, albumin demand continues to grow, but the amount of plasma is insufficient.
    but it is estimated that pulp production will largely resume outside Hubei at the end of March.
    Hualan biohass 11 varieties (34 specifications) such as human haemoglobin, static injection human immunoglobulin, human immunoglobulin, human coagulation enzyme complex, human coagulation factor VIII, rabies patient immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, etc.
    blood products originated in the early 1940s, after years of rapid development, product varieties have developed from the original human haemoglobin to human haemoglobin, immunoglobulin and coagulation factors and other more than 20 varieties.
    with the government and the public's increasing attention to the safety of blood products, governments gradually strengthen the supervision of the blood products industry, coupled with the merger and reorganization of enterprises, foreign blood products enterprises from the original more than 100 reduced to the current 20 or so.
    currently in Europe and the Developed Countries of the Americas, the consumption of blood products accounted for about 80% of the total consumption of global blood products, is the largest consumer market, per capita consumption of blood products is relatively high.
    in recent years, the blood products industry mergerand and integration, The four enterprises of Zhongsheng Group, Hualan Bio, Shanghai Laishi and Taibang Biological accounted for more than 50% of the total pulping volume in 2019, the industry concentration gradually increased.
    raw material plasma cost accounted for a higher proportion of the company's total production costs, is an important factor affecting the company's blood products costs, with the increasing of nutrition costs of plasma donors, the cost of plasma is gradually rising;
    other aspects, during the reporting period, gene company has 7 monoantiapiate varieties have obtained clinical trial approval, including Adamu monoid, quralmon, rituximatod, bevalsone has now entered the Phase III clinical research phase, denimonodin, panimonotide and ipimonostine has entered Phase I clinical research, is planned to start clinical trials, for the company to cultivate new profit growth points.
    the future, Hualan Bio will continue to apply for the construction of a new single plasma station, increase the publicity and launch of plasma donors to ease the tension of raw materialplasma plasma, continue to improve the comprehensive utilization rate of plasma through process optimization, new product development, technology upgrading, product restructuring; production and domestic and foreign sales, speed up the development and development of innovative drugs and biosimilar drugs, foster new profit growth points, enhance the company's core competitiveness, so that the company has developed into an international competitiveness, collection of blood products, vaccines, recombinant protein innovative drugs and biosimilar drugs research and development, production and sales of large-scale biopharmaceutical enterprises.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.